Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 6/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538853 | 0.91 | RPS6KB1 (0.56) | SIRT2RPS6KB1AURKATP53PARP1 | |
| SCHEMBL30776204 | 0.86 | GRIK1 (0.52) | SIRT2RPS6KB1AURKABRD4ATAD2 | |
| SCHEMBL7392417 | 0.85 | TP53 (0.66) | SIRT2TP53KDM4E | |
| SCHEMBL4497370 | 0.84 | AURKA (0.42) | SIRT2RPS6KB1AURKACDK1CDK4 | |
| Hydrochloric Acid SCHEMBL7385416 | 0.84 | TP53 (0.64) | SIRT2TP53KDM4E | |
| SCHEMBL14417232 | 0.84 | CHEK1 (0.48) | SIRT2RPS6KB1AURKATP53BRD4 | |
| SCHEMBL28528412 | 0.83 | KAT2B (0.46) | SIRT2RPS6KB1AURKACDK1CDK4 | |
| SCHEMBL29470849 | 0.83 | HSP90AA1 (0.55) | SIRT2TP53ROCK2 | |
| SCHEMBL4535105 | 0.83 | HSP90AA1 (0.55) | SIRT2TP53ROCK2 | |
| SCHEMBL3977642 | 0.82 | CHEK1 (0.59) | RPS6KB1AURKATP53PARP1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | claimed |
| CN-115916771-B | Multi-target antitumor compound and preparation method and application thereof | 浙江华海药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| WO-2016086153-A2 | USE OF TETRAHYDRO!NDAZOLYLBEIMZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | ESANEX, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-05-26 | — | — | US | disclosed |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20130137686-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-2029538-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1997818-A2 | Quinolinone derivatives and their use to treat pain | EURO-CELTIQUE S.A. (LU) | 2008-12-03 | — | — | EP | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2007144400-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144400-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | ESANEX, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137686-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | SIRT2 1328/4885RPS6KB1 1385/4885AURKA 1309/4885 |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | SIRT2 2956/4885RPS6KB1 2974/4885AURKA 4479/4885 |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | SIRT2 1984/4885RPS6KB1 80/4885AURKA 126/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | SIRT2 1328/4885RPS6KB1 1385/4885AURKA 1309/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | SIRT2 1984/4885RPS6KB1 80/4885AURKA 126/4885 |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | SIRT2 1328/4885RPS6KB1 1385/4885AURKA 1309/4885 |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | HSF1, HSPA4, HSP90AB1 | SIRT2 1043/4885RPS6KB1 71/4885AURKA 272/4885 |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | SIRT2 1328/4885RPS6KB1 1385/4885AURKA 1309/4885 |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | HSP90AB1, HSP90B1, HSP90AB2P | SIRT2 1769/4885RPS6KB1 201/4885AURKA 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.